DYSPAREUNIA TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Dyspareunia Treatment Market, By Drug Type (Selective Estrogen Receptor Modulators, Estrogens (Miscellaneous Vaginal Agents), Corticosteroids, Antibiotics, and Others), By Route of Administration (Oral, Vaginal Inserts, and Others), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, E-commerce, and Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East and Africa)

In December, 2023, DARÉ BIOSCIENCE, INC., a pharmaceutical company, announced that the U.S. Food and Drug Administration has cleared an investigational new drug (IND) application for DARE-VVA1, a tamoxifen currently being developed as a non-hormone therapy to be administered intravaginally in patients with moderate to severe dyspareunia, which often presents in menopausal patients with vulvar and vaginal atrophy (VVA). Tamoxifen is a selective estrogen receptor modulator often used to treat breast cancer, acting as an estrogen antagonist in breast tissue.
In June 2023, Cosette Pharmaceuticals, Inc., a pharmaceutical company, announced the acquisition of the global rights to Intrarosa, from Endoceutics, Inc., a subsidiary of Endorecherche, Inc., a pharmaceutical company. Intrarosa is the only prescription drug providing both estrogen and androgen for the treatment of moderate-to-severe dyspareunia (a common symptom of vulvar and vaginal atrophy (VVA) due to menopause).
In October 2021, Debiopharm, a biopharmaceutical company, Dexa Medica, a leading Indonesia-based pharmaceutical company, announced the launch of triptorelin in Indonesia for the treatment of women with gynecological disorders, particularly endometriosis.